We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lexicon and BMS Select Development Candidate for Neuropathic Pain
News

Lexicon and BMS Select Development Candidate for Neuropathic Pain

Lexicon and BMS Select Development Candidate for Neuropathic Pain
News

Lexicon and BMS Select Development Candidate for Neuropathic Pain

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lexicon and BMS Select Development Candidate for Neuropathic Pain"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lexicon Pharmaceuticals, Inc. has announced that the company and Bristol-Myers Squibb have selected a development candidate for neuropathic pain as part of their neuroscience drug discovery and development alliance.

Lexicon and Bristol-Myers Squibb are proceeding with plans to progress the development candidate through IND-enabling studies in preparation for the commencement of clinical trials.

Bristol-Myers Squibb has the first option under the alliance to obtain exclusive clinical development and commercialization rights upon the initiation of Phase 1 clinical studies, subject to the payment of milestones and royalties to Lexicon.

“The selection of this very promising drug candidate for neuropathic pain marks the culmination of a long-standing and highly-productive collaborative effort between Lexicon and Bristol-Myers Squibb,” said Lonnel Coats, Lexicon’s president and chief executive officer. “We look forward to bringing innovation from this novel mechanism to patients in an area of high unmet need.”

Advertisement